|
|
Article: Promise of Improved Productivity, Cost Savings to Boost Adoption of Computational Biology Tools by Drug Discovery Companies.
- Article from:
- PR Newswire Europe
- Article date:
- January 12, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LONDON, January 12 /PRNewswire/ --
- Lack of Validation Emerges as Major Restraint to Uptake
Computational biology tools are regarded as key to improving the productivity of the drug discovery process and introducing the efficiency of high-level computations to biology, which has hitherto been largely unaffected by the 'in-silico' revolution. However, while there have been occasional successes, a lot more rigorous validation and case studies are required to increase the penetration levels of computational biology tools in the drug discovery industry.
"Although many teething technical problems and lack of quality data are currently restraining ...